The optimal treatment for natural killer (NK) cell leukemia after chronic active Epstein-Barr virus (CAEBV) infection has not been determined. A 15-yearold boy presented with NK cell leukemia following CAEBV infection for 5 years. The peripheral blood and BM had an increased number of CD3 À CD56 + large granular lymphocytes and a monoclonal integration of the EBV genome was detected. Chemotherapy was not sufficiently effective to control the disease. Allogeneic BMT from an HLA-identical sister was performed using a conditioning regimen consisting of total body irradiation, cyclophosphamide and thiotepa. The patient is diseasefree with a perfect performance status 24 months after BMT. This is the first report to show that allogeneic BMT is potentially able to cure NK cell leukemia after CAEBV infection. Bone Marrow Transplantation (2003) 31, 1169-1171. doi:10.1038/sj.bmt.1704078 Keywords: chronic active Epstein-Barr virus (EBV) infection; NK cell leukemia; allogeneic bone marrow transplantation; EBV genome Chronic active Epstein-Barr virus (CAEBV) infection is an unusual disorder characterized by prolonged fever, wasting, hepatosplenomegaly and cytopenia, in addition to abnormal EBV antibody titers and the presence of EBV antigens or EBV DNA in tissue.
infection; NK cell leukemia; allogeneic bone marrow transplantation; EBV genome Chronic active Epstein-Barr virus (CAEBV) infection is an unusual disorder characterized by prolonged fever, wasting, hepatosplenomegaly and cytopenia, in addition to abnormal EBV antibody titers and the presence of EBV antigens or EBV DNA in tissue. [1] [2] [3] The prognosis for CAEBV infection is very poor and half of all patients die of multiorgan failure, infection, lymphoid malignancy and /or hemophagocytic syndrome within a few years. 3, 4 An effective treatment has yet to be established partly because CAEBV infection is rare. 3 Recently, allogeneic blood stem cell transplantation was reported to be effective in eradicating EBV-infected cells. 5, 6 Kuzushima et al 7 described that an adoptive transfer of anti-EBV cytotoxic T lymphocytes (CTLs) from an HLA-matched sibling to a patient with severe CAEBV infection transiently reduced the amount of EBV DNA, but was not able to completely eradicate the EBV infection.
Natural killer (NK) cell leukemia is a disease characterized by the clonal proliferation of CD3 À
CD56
+ large granular lymphocytes (LGL), originating from a subset of NK cells. The prognosis for NK cell leukemia is generally poor and most patients die within 1-2 months of diagnosis. 8 A standard therapy has not been established, although the efficacy of stem cell transplantation has been recently reported. 9, 10 The association of EBV infection and NK cell leukemia has been previously described, 11 and it was shown that the EBV genome was clonally integrated into leukemic NK cells. 12 Recently, a close relation between hypersensitivity to mosquito bites and EBV-infected NK cell proliferation was demonstrated. 13 It was reported that NK cell leukemia/lymphoma occasionally occurred after CAEBV infection and the prognosis was very poor. 3, 4 Here we describe a first such patient, who was successfully treated with allogeneic bone marrow transplantation (BMT) from an HLA-identical sibling donor.
Case report
A boy hypersensitive to bites from insects including mosquitoes was diagnosed as having CAEBV infection when 10 years old based on recurrent high-grade fevers, hepatosplenomegaly, pancytopenia and the presence of a large quantity of EBV DNA in plasma. The administration of prednisolone (PSL) relieved these symptoms; however, the disease recurred four times in 5 years. The patient was first treated with PSL and etoposide, a standard therapy for hemophagocytic lymphohistiocytosis in children, but responded poorly: his high fever, hepatosplenomegaly and pancytopenia worsened. Secondly, he received the CHOP (cyclophosphamide (CPM) 750 mg/m 2 Â 1, adriamycin (ADR) 50 mg/m 2 Â 1, vincristine (VCR) 1.4 mg/m 2 Â 1 and PSL 120 mg Â 5) regimen without significant effect and a huge hematoma because of intramuscular hemorrhage with severe acute pain appeared on his back 2 weeks later ( Figure 2 ). Finally, high-dose CPM (1200 mg/m 2 ) with PSL was initiated and the high fever and hepatosplenomegaly improved; however, the effect was transient. At this point, we decided to perform allogeneic BMT urgently.
His disease status was well-controlled with a second course of CPM and PSL. Just before BMT, the quantity of EBV DNA was consistently high (maximum; plasma: 4 Â 10 4 copies/ml, intracellular: 4 Â 10 4 copies/mgDNA) in peripheral blood. He received allogeneic BMT from an EBV-seropositive HLA-identical sibling donor. The conditioning therapy consisted of total body irradiation (TBI; 12 Gy in four fractions for 2 days; day À9, À8), thiotepa (150 mg/m 2 Â 2; day À7, À6) and CPM (60 mg/kg Â 2; day À4, À3). Prophylaxis for graft-versus-host disease (GVHD) was with PSL and short-term methotrexate (MTX; day +1, +3, +6). PSL was then replaced with cyclosporin A (CyA). Infection prophylaxis included acyclovir, fluconazole and ofloxacin. G-CSF (5 mg/kg/day) was used from day +5 to day +24. ANC40.5 Â 10 9 /l and platelet450 Â 10 9 /l occurred at day +18 and +36, respectively. A skin rash compatible with acute GVHD (grade I) was noted. Engraftment was confirmed on day +31 by karyotypic conversion from 46,XY to 46,XX in both the BM and peripheral blood. The post-BMT course was complicated with hemorrhagic cystitis because of CPM (onset: day À3), sepsis caused by Enterococcus faecium and Staphylococcus epidermidis (MRSE) (day +9) and miliary tuberculosis (day +19). A specific treatment was performed for each event. The EBV genome in the peripheral blood became negative after BMT ( Figure 3) . As of writing, the patient is clinically well (performance status: 100%) in sustained complete remission without medication 24 months after BMT.
Discussion
NK cell leukemia is a rare disease, the prognosis which is dismal. Since NK cells express p-glycoprotein, 14 they are usually resistant to cytotoxic agents such as anthracyclines, epipodophylotoxins and vinca alkaloids. Steroids and alkylating agents do not interact with p-glycoprotein and may be key drugs for the treatment of NK cell leukemia. We previously reported that long-term remission was induced by a combination of corticosteroids and CPM, although relapse occurred after 2 years of treatment. 15 Based on previous data, we first treated our patient with PSL and CPM as induction therapy. The clinical symptoms The amount of EBV genome was calculated using the copy number of virus with real-time PCR method. Square and round show the quantity of EBV genome in the mononuclear cells and plasma of peripheral blood, respectively. improved transiently, but EBV DNA and EBV-infected leukemic cells remained.
Recently, the efficacy of allogeneic BMT for both CAEBV infection and NK cell leukemia was shown. 9, 10 Based on these results, we performed a BMT from an HLA identical sibling for our patient with NK cell leukemia following CAEBV infection for 5 years. A marked decrease in the amount of EBV genome and the disappearance of clinical signs soon followed the BMT (Figure 2) . Regarding conditioning regimens, we employed TBI and two kinds of alkylating agents: CPM and thiotepa. Although a prospective trial is mandatory, this regimen may be optimal for NK cell disease, since it was also successful in a case of relapsed blastic NK cell lymphoma when used with unrelated cord blood support. 16 The patient is clinically well in sustained hematological complete remission for 24 months since BMT. A close relation between EBV infection and NK cell leukemia was previously suggested, although the exact role of EBV in the leukemogenesis of NK cell diseases has not been fully elucidated. The measurement of the EBV genome could be utilized as a tumor marker of NK cell leukemia, and realtime PCR was very useful in monitoring the residual leukemia cells, as suggested by Kimura et al. 17 This patient presented with miliary tuberculosis soon after allogeneic BMT and required intensive therapy. The long-term use of steroids (for 5 years in this case) has a well-known association with tuberculosis. The possibility of tuberculosis should always be considered when severely immunosuppressed patients develop pneumonitis after BMT. A detailed description of the clinical course of tuberculosis in this patient will be reported separately.
In conclusion, chemotherapy using steroids and alkylating agents has a limited effect on the eradication of NK leukemic cells. Allogeneic BMT is potentially a curable strategy for those with NK cell leukemia following a longstanding EBV infection.
